martes, 6 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 21, 2026

Social Security's 2027 Cost-of-Living Adjustment (COLA) May Be Among the Largest in 25 Years -- but There's a Catch

View original at nasdaq.com
Social Security's 2027 Cost-of-Living Adjustment (COLA) May Be Among the Largest in 25 Years -- but There's a Catch Key Points Social Security's annual COLA reveal in October is arguably the most anticipated announcement of the year for program recipients…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • A larger-than-expected COLA in 2027 won't change the fact that a Social Security dollar simply isn't what it used to be

    60% confidence
  • The purchasing power of Social Security income declined 36% from the start of the 21st century to February 2023

    60% confidence
  • Gas prices in the US have moved up to $3.79/gallon, their highest level since September 2023. The 30% spike over the last month ($2.92/gallon to $3.79/gallon) is the biggest we've seen in the past 30 years.

    60% confidence
  • The purchasing power of Social Security income dropped 20% from 2010 to 2024

    60% confidence
  • There's a real possibility of the 2027 COLA being among the largest over the last quarter century

    60% confidence
  • Medicare's Part B premium is rising at a significantly faster pace than Social Security's annual COLA more often than not

    60% confidence
  • Social Security benefits will rise by 1.7% in 2027

    60% confidence
  • Social Security benefits will increase by 2.8% in 2027

    60% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com